Psyence Group Inc. (TSE:PSYG) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Psyence Group Inc. is advancing in the mental health sector by having its associate, Psyence Biomed, partner with Fluence and iNGENū CRO to facilitate training for a Phase IIb clinical trial involving psilocybin, a natural psychedelic compound. The collaboration aims to integrate psychedelic-assisted therapy for palliative medicine, with a trial set to begin in the second quarter of 2024, testing psilocybin in conjunction with psychotherapy on 84 patients. Psyence Group, known for its federally licensed commercial psilocybin production facility, holds a significant minority interest in Psyence Biomed.
For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.